“
TL;DR
The assay relies on the reduction of Cu²⁺ to Cu¹⁺ by sample antioxidants, followed by colorimetric detection of the BCA–Cu¹⁺ chelate at 570 nm.
STAR Protocols · 4 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The assay relies on the reduction of Cu²⁺ to Cu¹⁺ by sample antioxidants, followed by colorimetric detection of the BCA–Cu¹⁺ chelate at 570 nm.
The assay relies on the reduction of Cu²⁺ to Cu¹⁺ by sample antioxidants, followed by colorimetric detection of the BCA–Cu¹⁺ chelate at 570 nm. The protocol exhibited stable linear performance across pH 4 to pH 10 and at room temperature. Limitations include measurement of only Cu²⁺-reducible antioxidants, primarily hydrophilic activity, and the need for prompt −80°C storage of clinical specimens.